JAGX
Jaguar Health, Inc.
$2.31
-0.06 (-2.53%)
At close · Jul 10
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements.”View the 10-Q filed May 20, 2026
Market Cap
$1.39M
Shares
603,134
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$11.51M
-1.5%
FY2025
Net Income
-$53.58M
-136396.8%
FY2025
Gross Margin
67.21%
-16.1pp
FY2025
Operating Margin
-398.82%
-135.1pp
FY2025
Diluted EPS
-$803.95
+82.4%
FY2025
Operating Cash Flow
-$23.69M
+19.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $29.57M | $11.51M | $11.69M | — | $11.96M | — | $9.39M | $5.78M | $4.42M | $4.36M | $141.52K | $258.38K | |
| $4.42M | $3.77M | $1.96M | $2.04M | $2.02M | $2.33M | $3.28M | $3.82M | $2.77M | $880.41K | $51.97K | $123.46K | |
| $25.15M | $7.74M | $9.73M | — | $9.94M | — | $6.11M | $1.96M | $1.65M | $3.48M | $89.56K | $134.92K | |
| — | 67.21% | 83.27% | — | 83.11% | — | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | |
| $25.16M | $24.97M | $16.54M | $18.6M | $17.65M | $15.08M | $6.41M | $5.82M | $5.15M | $4.27M | $7.21M | $6.48M | |
| $7.64M | $9.24M | $7.69M | $6.46M | $8.84M | $8.89M | $6.61M | $6.94M | $9.83M | $3.08M | $485.44K | $765.09K | |
| $17.86M | $18.64M | $16.33M | $16.59M | $17.87M | $17.1M | $14.39M | $13.5M | $12.28M | $11.25M | $5.98M | $5.34M | |
| $1.9M | $1.9M | $1.9M | $2M | $1.8M | $1.7M | $1.7M | $1.69M | $1.69M | — | — | — | |
| — | $1.91M | $1.9M | $2.01M | $1.98M | $1.72M | $1.73M | $1.74M | $1.32M | $584.34K | $47.49K | $5155 | |
| $36.67M | — | — | — | — | — | — | — | $35.24M | $38.61M | $13.73M | $12.7M | |
| $55.87M | $57.42M | $42.52M | $44.05M | $46.37M | $45.04M | $36.03M | $34.72M | — | — | — | — | |
| -$26.31M | -$45.91M | -$30.83M | -$34.29M | -$34.42M | -$40.71M | -$26.65M | -$28.95M | -$30.82M | -$34.25M | -$13.59M | -$12.45M | |
| — | -398.82% | -263.76% | — | -287.85% | — | -283.93% | -501.24% | -697.98% | -785.27% | -9599.84% | -4816.67% | |
| — | -$44M | -$28.93M | -$32.28M | -$32.43M | -$38.99M | -$24.92M | -$27.21M | -$29.5M | -$33.66M | -$13.54M | -$12.44M | |
| $822K | $67K | $231K | $6.38M | $12.72M | $8.42M | $2.79M | $5.73M | $2.63M | $1.21M | $985.55K | $3.32M | |
| $136K | $43K | $51K | $200K | $950K | -$765K | $190K | $80.83K | $315.69K | $88.55K | -$11.05K | -$27.28K | |
| — | -$162K | -$138K | -$51K | — | — | — | — | — | — | — | — | |
| -$34.68M | -$54M | -$39.25M | -$41.9M | -$48.4M | -$52.6M | -$33.81M | -$38.53M | -$32.15M | -$35.15M | — | — | |
| — | $0 | $0 | — | $0 | $0 | $10K | $10K | -$13.18M | -$13.18M | — | — | |
| -$34.26M | -$53.58M | -$39.25K | -$41.3M | -$48.4M | -$52.6M | -$33.81M | -$38.54M | -$32.15M | -$21.97M | -$14.73M | -$16.29M | |
| — | -465.42% | -0.34% | — | -404.78% | — | -360.25% | -667.32% | -727.92% | -503.73% | -10410.87% | -6305.24% | |
| -$557K | -$563K | -$759K | -$601K | -$941K | -$5000 | — | — | — | — | — | — | |
| -$50.13M | -$53.58M | -$38.49M | -$41.3M | -$47.45M | -$52.6M | — | — | -$32.15M | -$21.97M | -$14.73M | -$16.64M | |
| -$50.67M | -$53.94M | -$38.31M | -$41.27M | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$803.95 | -$4,574.15 | -$93,975.00 | -$1,899,450.00 | -$4,646,250.00 | — | — | — | — | — | — |
| USD/shares | — | -$803.95 | -$4,574.15 | -$93,975.00 | -$1,899,450.00 | -$4,646,250.00 | — | — | — | — | — | — |
| shares | — | 66.64K | 8415.2571 | 439.3985 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 1.2428 | 3.6771 | 0.9271 | 0.5209 |
| shares | — | 66.64K | 8415.2571 | 439.3985 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 1.2428 | 3.6771 | 0.9271 | 0.5209 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2019: $60 in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Human Health Segment | $11,158,000 | $11,374,000 | $9,588,000 |
| Animal Health Segment | $353,000 | $315,000 | $173,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Product | $11,339,000 | $11,560,000 | $9,761,000 | — | $4,335,000 | — |
| Mytesi | $11,000,000 | $11,300,000 | $9,600,000 | $11,700,000 | $4,300,000 | $9,300,000 |
| License | $172,000 | $129,000 | — | — | — | — |
| Canalevia | $148,000 | $160,000 | $130,000 | $167,000 | — | — |
| Neonorm | $35,000 | $28,000 | $42,000 | $48,000 | $62,000 | $76,000 |